These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 9787988)

  • 21. [Medication of the month. Tazarotene 0.05%-0.1% (Zorac)].
    Henno A; Hua MT; de la Brassinne M
    Rev Med Liege; 2003 Nov; 58(11):706-8. PubMed ID: 14748200
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy.
    Tanghetti E; Lebwohl M; Stein Gold L
    J Drugs Dermatol; 2018 Dec; 17(12):1280-1287. PubMed ID: 30586259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment options for psoriasis.
    McClelland PB
    Dermatol Nurs; 1997 Oct; 9(5):295-304; quiz 305-6. PubMed ID: 9392761
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the potential clinical benefits of switching patients with plaque psoriasis from calcipotriene to tazarotene treatment.
    Coynik D
    Cutis; 2000 Dec; 66(6 Suppl):19-24. PubMed ID: 11147087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of topical tazarotene: a review.
    Talpur R; Cox K; Duvic M
    Expert Opin Drug Metab Toxicol; 2009 Feb; 5(2):195-210. PubMed ID: 20213916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model.
    Sun J; Dou W; Zhao Y; Hu J
    Immunopharmacol Immunotoxicol; 2014 Feb; 36(1):17-24. PubMed ID: 24286371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The management of psoriasis-tazarotene: the bottom line.
    Weinstein GD
    Cutis; 1998 Feb; 61(2 Suppl):38-9. PubMed ID: 9787992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prescribe topical treatments for psoriasis].
    Lorette G; Fontès V
    Rev Prat; 2004 Jan; 54(1):40-2. PubMed ID: 15049598
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tazarotene--a topical retinoid for psoriasis.
    Drug Ther Bull; 1999 Jun; 37(6):47-8. PubMed ID: 10692712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short contact therapy with tazarotene in psoriasis vulgaris.
    Veraldi S; Caputo R; Pacifico A; Peris K; Soda R; Chimenti S
    Dermatology; 2006; 212(3):235-7. PubMed ID: 16549919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tazarotene 0.1% gel in the treatment of fingernail psoriasis: a double-blind, randomized, vehicle-controlled study.
    Scher RK; Stiller M; Zhu YI
    Cutis; 2001 Nov; 68(5):355-8. PubMed ID: 11766122
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tazarotene induces epidermal cell differentiation in the mouse tail test used as an animal model for psoriasis.
    Sebök B; Bonnekoh B; Kerényi M; Gollnick H
    Skin Pharmacol Appl Skin Physiol; 2000; 13(5):285-91. PubMed ID: 10940819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical tazarotene: a review of its use in the treatment of plaque psoriasis.
    Dando TM; Wellington K
    Am J Clin Dermatol; 2005; 6(4):255-72. PubMed ID: 16060713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obtaining the optimal treatment outcome with tazarotene.
    McClelland PB
    Dermatol Nurs; 1998 Oct; 10(5):343-8. PubMed ID: 9873273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Meta-analysis of topical tazarotene in the treatment of mild to moderate acne.
    Leyden JJ
    Cutis; 2004 Oct; 74(4 Suppl):9-15. PubMed ID: 15543714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disposition and biotransformation of the acetylenic retinoid tazarotene in humans.
    Attar M; Yu D; Ni J; Yu Z; Ling KH; Tang-Liu DD
    J Pharm Sci; 2005 Oct; 94(10):2246-55. PubMed ID: 16136553
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An observation study evaluating the efficacy of tazarotene plus corticosteroid in treating plaque psoriasis in patients switched from treatment with calcipotriene +/- corticosteroid.
    Tanghetti EA;
    Cutis; 2000 Dec; 66(6 Suppl):12-8. PubMed ID: 11147086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy of topical tazarotene monotherapy and combination therapies in psoriasis.
    Koo J; Behnam SE; Behnam SM
    Expert Opin Pharmacother; 2003 Dec; 4(12):2347-54. PubMed ID: 14640932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Childhood nail psoriasis: a useful treatment with tazarotene 0.05%.
    Diluvio L; Campione E; Paternò EJ; Mordenti C; El Hachem M; Chimenti S
    Pediatr Dermatol; 2007; 24(3):332-3. PubMed ID: 17542899
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topical tazarotene vs. coal tar in stable plaque psoriasis.
    Kumar U; Kaur I; Dogra S; De D; Kumar B
    Clin Exp Dermatol; 2010 Jul; 35(5):482-6. PubMed ID: 19874376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.